CBD for Quitting Smoking: What the Research Says

An Honest Look at a Complicated Subject

CBD shows early scientific promise for smoking cessation. Two small trials suggest it can reduce cigarette consumption and weaken the automatic pull toward smoking cues. The evidence is also thin enough that you shouldn’t build your quit plan around it: the studies are small, the products are unregulated, and nobody has established the right dose.

That said, the research is worth knowing. If you’re considering CBD as part of your quit plan, you deserve the full picture: what the science actually found, what it didn’t, and where it sits relative to approaches that have been tested on hundreds of thousands of people.

I looked into this during one of my own quit attempts, willing to try just about anything that might blunt the edge. What I found was interesting enough to take seriously, and incomplete enough to keep perspective.

The Research: What We Actually Know

The 2013 UCL Pilot Study

The study that put CBD and smoking cessation on the map was conducted at University College London and published in Addictive Behaviors in 2013.

The design: 24 smokers were randomly assigned to receive either a CBD inhaler or a placebo inhaler. They used the inhaler whenever they felt the urge to smoke, over one week.

The results: The CBD group reduced their cigarette consumption by approximately 40% over the study week. The placebo group showed no significant change. That’s a meaningful gap for any cessation intervention, and it’s the number that put CBD on researchers’ radar.

The limitations: The sample was tiny: 24 people split into two groups of 12. The study ran for one week with no long-term follow-up. The inhaler was a custom research device, not a commercial product you can buy anywhere. And the study measured reduction in cigarettes smoked, not abstinence: nobody confirmed whether participants actually quit.

Despite those caveats, a 40% reduction generated real scientific interest and funded the follow-up research that came after.

The 2018 Attentional Bias Study

A study published in Addiction in 2018, also from UCL researchers, explored a specific mechanism: whether CBD could reduce the attentional bias smokers have toward cigarette-related cues.

What is attentional bias? When you’re addicted to something, your brain automatically notices cues connected to that substance. A smoker’s eyes are drawn to other people lighting up, to lighters on tables, to ashtrays. This happens below conscious awareness and is a powerful driver of cravings and relapse.

The design: 30 smokers received either 800mg of oral CBD or a placebo in a single dose, then viewed cigarette-related and neutral images while researchers tracked eye movements and reaction times.

The results: CBD reduced attentional bias toward cigarette cues. Participants on CBD spent less time fixating on cigarette-related images compared to the placebo group. CBD didn’t dramatically reduce craving intensity on its own, but it weakened the automatic pull toward smoking-related stimuli.

This matters because it points to a mechanism different from nicotine replacement therapy, which replaces the substance, or varenicline, which blocks nicotine receptors. CBD appears to work at the level of attention and habit: the unconscious tug toward smoking that makes quitting so much harder than “just deciding.”

The 2022 Hindocha et al. Follow-Up

Morgan and Hindocha’s research group continued exploring CBD for tobacco cessation. Their work has included investigation into memory reconsolidation: the process by which established memories are recalled, briefly destabilized, and then re-stored.

The theory is that if CBD can interfere with reconsolidation of smoking-related memories, it might weaken the association between cigarettes and reward at a neurological level. This remains speculative in human smokers, though it builds on animal model data consistently showing CBD reduces reinstatement of drug-seeking behavior across multiple substances.

Other Relevant Research

Animal studies have shown CBD reduces drug-seeking and relapse behavior for heroin, cocaine, and alcohol. Multiple randomized controlled trials confirm CBD’s anxiolytic effects in humans: a well-cited study in Neuropsychopharmacology found CBD significantly reduced anxiety during simulated public speaking in people with social anxiety disorder. As of early 2026, no large-scale RCT has been completed specifically for smoking cessation using CBD. That is the key gap.

How CBD Might Help (The Proposed Mechanisms)

No single mechanism has been definitively confirmed, but several plausible pathways have been identified.

1. Anxiety Reduction

CBD has well-documented anti-anxiety effects in human trials. Since anxiety is both a trigger for smoking and one of the most uncomfortable withdrawal symptoms, reducing anxiety during a quit attempt could meaningfully improve outcomes. Many people smoke specifically to manage anxiety: if CBD partially substitutes for that function, the cigarette becomes less necessary.

2. Disruption of Habit Loops

The attentional bias research suggests CBD weakens the automatic connection between environmental cues and the urge to smoke. Habit loops operate below conscious control: cue, craving, behavior, reward. Any intervention that loosens the cue-craving link gives the rational, decision-making part of your brain a better chance to intervene.

3. Effects on the Endocannabinoid System

The endocannabinoid system plays a role in reward processing, stress response, and habit formation. CBD interacts with this system without binding to CB1 receptors the way THC does. The hypothesis is that CBD modulates the reward pathways nicotine has hijacked, making cigarettes feel less reinforcing without producing intoxication.

4. Sleep Improvement

Disrupted sleep is one of the most common withdrawal symptoms and a significant relapse trigger. Some evidence suggests CBD may improve sleep quality and reduce the time it takes to fall asleep. Better sleep during the first weeks of quitting would reduce the fatigue and irritability that push people back to smoking.

What We Don’t Know (And It’s a Lot)

The honest accounting of gaps is substantial:

• No large-scale RCT for smoking cessation with CBD has been completed
• Optimal dose is unknown: the 2018 study used 800mg; most commercial products deliver 10-50mg per serving
• Whether commercial CBD products are bioequivalent to research-grade formulations is untested
• Long-term abstinence rates using CBD have never been measured
• Whether CBD adds benefit on top of NRT or prescription cessation medication is unknown
• Which smokers benefit most has not been studied: anxiety-driven smokers, heavy users, and habit-dominant smokers may respond very differently

The dose discrepancy deserves attention. The most rigorous human study used 800mg of pharmaceutical-grade CBD in a single dose. A typical commercial CBD gummy contains 10-25mg. Whether that gap matters, or whether the mechanisms that showed results in the trial operate at much lower doses, nobody has tested in a controlled trial.

The FDA Situation

As of 2026, CBD is not FDA-approved for smoking cessation. The only FDA-approved CBD product is Epidiolex, which is approved for specific seizure disorders.

CBD supplements sold in stores and online are regulated as food supplements, not medications. That means:

• No requirement to prove efficacy before sale
• No standardized manufacturing oversight
• No guarantee the label matches the contents (third-party testing has documented significant mislabeling in commercial CBD products)
• No established dosing guidelines for any indication beyond Epidiolex

This doesn’t mean CBD doesn’t work. It means the product you buy might not contain what the label says, and no government agency is auditing the store shelf for you.

If You Want to Try CBD: A Practical Guide

Choose Quality Products

Look for a Certificate of Analysis (COA) from an independent third-party laboratory. The COA should confirm CBD potency and screen for pesticides, heavy metals, and residual solvents. Brands that won’t publish COAs or only provide in-house testing are worth skipping entirely. Expect to pay more for reputable products: the $8 gas station CBD is where quality goes to die, and the research doses used in clinical trials cost significantly more to produce than that.

Routes of Administration

Sublingual tinctures (drops held under the tongue for 60-90 seconds) offer the fastest onset outside of inhalation, typically 15-45 minutes. They’re the most practical option for responding to acute cravings as they arise.

Oral formats (capsules, gummies) take 1-2 hours to kick in but last longer. Less useful for craving-triggered use, better for baseline daily support.

Inhalation has the fastest onset but introduces lung exposure: the same concern you’re trying to escape by quitting smoking. Skip it.

Dosing Considerations

There’s no established dose for smoking cessation. Based on general CBD research:

• Start low: 15-25mg per day as a baseline
• For craving-triggered use: 15-30mg sublingual at craving onset
• Give it 2-3 weeks before deciding it isn’t helping
• Keep in mind the 2018 study used 800mg, far above what standard OTC products deliver, so the effective cessation dose may be meaningfully higher than typical supplement use

Side effects can include drowsiness, dry mouth, diarrhea, and appetite changes. Most people tolerate CBD well at standard doses, but individual responses vary.

Important Precautions

CBD inhibits certain liver enzymes (CYP2D6 and CYP3A4) and can significantly raise blood levels of other medications. Warfarin is the most documented interaction. If you take blood thinners, certain antidepressants, antiseizure medications, or any drug with a narrow therapeutic window, talk to your doctor before starting CBD.

Full-spectrum products contain trace amounts of THC and can produce a positive drug test. If you face workplace drug testing, use broad-spectrum or isolate products instead.

CBD vs. Proven Cessation Methods: Perspective

Method	Evidence Quality	Approximate Effect	FDA-Approved
NRT (patch, gum, lozenge)	Very strong (130+ trials)	50-60% improvement over placebo	Yes
Varenicline (Chantix)	Very strong	Roughly triples quit rate vs. placebo	Yes
Bupropion (Wellbutrin/Zyban)	Strong	Roughly doubles quit rate vs. placebo	Yes
Behavioral counseling	Strong	Significantly improves all methods	N/A
CBD	Very limited (small pilots)	Unclear; dose unknown	No

The evidence gap is significant. This doesn’t mean CBD is worthless: it means we’re comparing a well-established toolkit against a hypothesis that’s still being tested. If you’re looking at success rates by method and want the best odds, proven approaches are your foundation. CBD as supplementary support is a reasonable experiment: just don’t bet your quit on it.

What the Future Might Look Like

Research into CBD for substance use disorders is accelerating. The National Institute on Drug Abuse (NIDA) has expressed interest in cannabinoid-based approaches to addiction treatment, and larger trials are in planning or progress.

If the early results hold in larger studies, CBD could eventually become an adjunct in the standard cessation toolkit, similar to how exercise is recommended alongside medication rather than instead of it. It’s unlikely to replace NRT or prescription medications. But a well-tolerated, widely available tool that reduces anxiety and disrupts automatic smoking behaviors would fill a real niche.

That’s a plausible future. Not a certainty.

The Bottom Line

CBD for smoking cessation is a “maybe.” The 2013 pilot showing a 40% reduction in cigarette consumption is hard to dismiss. The 2018 attentional bias research adds a plausible mechanism. But “promising” and “proven” are different words for a reason.

If you want to add CBD to your quit strategy:

• Use proven methods (NRT, prescription medication, counseling) as your foundation
• Treat CBD as supplementary support, not the main event
• Buy products with a third-party COA, not whatever’s cheapest on the shelf
• Start low on dose and give it several weeks
• Tell your doctor, especially if you take any medications that interact with CYP enzymes

Nicotine addiction doesn’t have magic bullets. But there are tools, supports, and sometimes substances that take the edge off just enough to give your resolve a fighting chance. CBD might be one of those tools. The research doesn’t close the case in either direction.

Try. Track. Adjust.

Sources and Further Reading

• Morgan CJA, Das RK, Joye A, Curran HV, Bhattacharyya S. Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addictive Behaviors. 2013;38(9):2433-2436.
• Hindocha C, Freeman TP, Grabski M, et al. Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco craving: a randomised, double-blind, placebo-controlled study. Addiction. 2018;113(9):1696-1705.
• Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015;12(4):825-836.
• Zuardi AW, et al. Effects of ipsapirone and cannabidiol on human experimental anxiety. Journal of Psychopharmacology. 1993;7(1 Suppl):82-88.
• World Health Organization. Cannabidiol (CBD) Critical Review Report. Expert Committee on Drug Dependence. 2018.
• National Institute on Drug Abuse. Research on cannabinoids and addiction treatment. nih.gov.